News for Antisense Therapeutics Limited (ANP.AX)

Incannex Healthcare Inc (IXHL) has experienced a remarkable surge in its stock price, with an 800.00% gain over the past week and an impressive 519.15% increase

Incannex Healthcare Inc (IXHL) has experienced a remarkable surge in its stock price, with a 768.48% gain over the past week and an impressive 451.03% gain over

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.20% to 7,073.20.

Visiongain has published a new report entitled Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033: Forecasts by Therapeutic Application...

Futures indicate the ASX is set to open lower as the new week begins, following a relatively flat close on Wall Street at the end of last week.

Futures suggest the ASX will open lower today following weak tech trading on Wall Street overnight.

Little Green Pharma (ASX:LGP) was reappointed as a primary supplier of its 1:20 THC:CBD medicinal cannabis oil to the French government trial.

CardieX (ASX:CDX) announced the US FDA has granted 510(k) clearance for its CONNEQT Pulse vascular biometric monitor.

Antisense Therapeutics (ASX:ANP) has commenced the dosing stage of a nine-month chronic monkey toxicology study of its ATL1102 treatment in the US.

Radiopharmaceutical specialist, Clarity Pharma (ASX:CU6), has announced favourable results from its Phase I clinical trial.

Emyria (ASX:EMD) says it has secured sufficient clinical-grade MDMA to support its MDMA-assisted therapy for over 70 patients.

The ASX has made modest gains this morning, but Lode Resources' massive silver hit has the company flying high, past +135%. Amazing.

Visiongain has published a new report entitled Antisense Oligonucleotide Therapeutics 2022-2032. It includes profiles of Antisense Oligonucleotide...

ASX health stocks are comfortably up this week after better than expected US inflation figures for October have boosted markets.

Visiongain has published a new report entitled Antisense Oligonucleotide Therapeutics 2022-2032. It includes profiles of Antisense Oligonucleotide...

Read Antisense Therapeutics Limited (ASX:ANP) Insider Ben Price Acquires 493,896 Shares at ETF Daily News

Winter’s nearly over and the Covid surge in Australia has slowed down dramatically. New cases are now rapidly declining.

World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers...

The world could start running out of cobalt soon, three energy stocks set for action, and clean up in Aisle IPO.